This study, called xPedite, is gathering information from new and existing patients with diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). It's an observational study, meaning researchers will collect medical records and information reported by patients, families, or caregivers. The goal is to better understand how these diseases progress naturally. This information can then be used to help design future studies for new treatments. You can join if you have a diagnosis of diffuse midline glioma, including DIPG, based on WHO 2021 criteria. If a biopsy isn't available, a grade IV glioma in certain brain or spinal cord areas also qualifies. The main thing researchers will be looking at is how long patients live (Overall Survival) at 12 months. The current status of this study is unclear.

Study design

This is an observational study aiming to enroll 400 participants. It is a virtual, decentralized, nationwide study that collects real-world data.

What's involved

You will participate by giving eConsent to the XCELSIOR master observational protocol. Medical records will be accessed directly from institutions, patient portals, and sequencing vendors.

Compensation

Not stated in the trial record.

Follow-up

Overall Survival will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.